421-435 of 894
Lillian Siu, MD, FRCPC
A Unique Look at the Current and Future Directions of Cancer Vaccines
Project Oncology®A Unique Look at the Current and Future Directions of Cancer Vaccines
Lillian Siu, MD, FRCPC
Updates on New Technologies and Imaging Agents in Healthcare
Project Oncology®Updates on New Technologies and Imaging Agents in Healthcare
Tyler J Bradshaw, PhD
The Power of Patient Advocacy in Daily Clinical Practice
Project Oncology®The Power of Patient Advocacy in Daily Clinical Practice
Ashley L. Sumrall, MD
Ashley L. Sumrall, MD
Targeting RET Alterations: Selpercatinib's Role in Pediatric Thyroid Cancer
Project Oncology®Targeting RET Alterations: Selpercatinib's Role in Pediatric Thyroid Cancer
- advertisement
Real-World Data on Treatment Choices for mccRCC
Project Oncology®Real-World Data on Treatment Choices for mccRCC
Thyroid Cancer and Gender-Affirming Hormone Therapy: Exploring a Potential Link
Project Oncology®Thyroid Cancer and Gender-Affirming Hormone Therapy: Exploring a Potential Link
Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Project Oncology®Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Project Oncology®Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Project Oncology®Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
Oncology and HematologySunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
- advertisement
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Oncology and HematologyTAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Oncology and HematologyUpdates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Oncology and HematologyTAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
